Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

(2022) Raquel Viana et al.   NATURE

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

(2022) Hung Fu Tseng et al.   NATURE MEDICINE

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

(2022) Mark G. Thompson et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021

(2022) Amelia G. Johnson et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021

(2022) Mark W. Tenforde et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Genetic Variants of SARS-CoV-2—What Do They Mean?

(2021) Adam S. Lauring et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines

(2021) Joseph A. Lewnard et al.   EPIDEMIOLOGY

Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States

(2021) Mark W Tenforde et al.   CLINICAL INFECTIOUS DISEASES

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

(2021) Aziz Sheikh et al.   LANCET

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

(2021) Katherine A Twohig et al.   LANCET INFECTIOUS DISEASES

Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization

(2021) Minal K. Patel et al.   VACCINE

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021

(2021) Mark W. Tenforde et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

(2021) Wesley H. Self et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity

(2021) Mark W. Tenforde et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

(2021) Shirley Collie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance — COVID-NET, 14 States, January–August 2021

(2021) Christopher A. Taylor et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

A minimal common outcome measure set for COVID-19 clinical research

(2020) John C Marshall et al.   LANCET INFECTIOUS DISEASES

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

(2020) Andrew Rambaut et al.   Nature Microbiology

Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness

(2016) Sheena G. Sullivan et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY